MedTrace Logo

Colistin Plus Rifampicin in MDR P. Aeruginosa and A. Baumanii

NCT01297855 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2012-01-02

No results posted yet for this study

Summary

In Siriraj Hospital, Colistin alone for treatment of MDR. A.baumanii or P.aeruginosa contributed to mortality 45%. In vitro studies revealed synergism of Rifampicin and Colistin.

In this study, patients with documented MDR. P.aeruginosa or A.baumanii will be allocated to receive Colistin alone and another group will receive Colistin plus Rifampicin.

Conditions

  • Drug Safety

Interventions

DRUG

Colistin

Colistimethate Sodium dose 2.5-5mg/kg/day

DRUG

Colistin plus Rifampicin

Colistin 2.5 to 5 mg/ Kg/ day Rifampin 10 mg/ Kg/ day

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Principal Investigators

  • Sukij Piyasirisilp, MD · Siriraj Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-05-31
Completion
2012-08-31

Countries

  • Thailand

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01297855 on ClinicalTrials.gov